23 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Nov 2030
Next term end
17
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2033 · High confidence
Also notable
Ends Mar 2037 · High confidence
Also notable
Ends Mar 2041 · High confidence
Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure
US 9,617,550
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2033.
Small Antibody-Like Polypeptides That Bind to EPHA2 Receptor
US 10,829,558
Cited by 11 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.
Endoscope Designs and Methods of Manufacture
US 11,561,387
The newest of the three, granted 2023. It anchors the portfolio to 2041, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Cordless Disposable Endoscope (US 11,737,648) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 13, 2027The maintenance fee for CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds (US 9,156,917) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure (US 11,866,715) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure (US 10,612,033) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 17 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure | 6 in force | to Oct 2033 |
| Ribotoxin Molecules Derived from Sarcin and Other Related Fungal Ribotoxins | 2 in force | to Mar 2034 |
| Endoscope Designs and Methods of Manufacture | 1 in force | to Mar 2041 |
| Engineered Stable CH2 Polypeptides | 1 in force | to May 2039 |
| Small Antibody-Like Polypeptides That Bind to EPHA2 Receptor | 1 in force | to Mar 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,303,964 | Viable Non-Toxic Gram-Negative Bacteria In force · High confidence | In force | High confidence | |
| US 8,440,456 | Nucleic Acids of Pichia Pastoris and Use Thereof for Recombinant Production of Proteins In force · High confidence | In force | High confidence | |
| US 9,068,186 | Viable Gram Negative Bacteria Lacking Outer Membrane Agonists of TLR4/MD-2 In force · High confidence | In force | High confidence | |
| US 9,458,454 | Viable Gram Negative Bacteria with Reduced Proteolytic Activity Lacking Outer Membrane Agonists of TLR4/MD-2 In force · High confidence | In force | High confidence | |
| US 9,156,917 | CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds In force · High confidence | In force | High confidence | |
| US 9,617,550 | Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure In force · High confidence | In force | High confidence | |
| US 10,113,164 | Pichia Pastoris Surface Display System In force · High confidence | In force | High confidence | |
| US 10,329,572 | Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure In force · Low confidence | In force | Low confidence | |
| US 10,612,033 | Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure In force · High confidence | In force | High confidence | |
| US 11,220,692 | Pichia Pastoris Strains for Producing Predominantly Homogeneous Glycan Structure In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 31 patents ended · 1 application pending · 16 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.